AMABELZ Drug Patent Profile
✉ Email this page to a colleague
When do Amabelz patents expire, and what generic alternatives are available?
Amabelz is a drug marketed by Lupin Ltd and is included in one NDA.
The generic ingredient in AMABELZ is estradiol; norethindrone acetate. There are seventy-five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the estradiol; norethindrone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amabelz
A generic version of AMABELZ was approved as estradiol; norethindrone acetate by BRECKENRIDGE PHARM on April 17th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AMABELZ?
- What are the global sales for AMABELZ?
- What is Average Wholesale Price for AMABELZ?
Summary for AMABELZ
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Patent Applications: | 44 |
| Drug Prices: | Drug price information for AMABELZ |
| DailyMed Link: | AMABELZ at DailyMed |
US Patents and Regulatory Information for AMABELZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | AMABELZ | estradiol; norethindrone acetate | TABLET;ORAL | 203339-001 | Jun 20, 2016 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Lupin Ltd | AMABELZ | estradiol; norethindrone acetate | TABLET;ORAL | 203339-002 | Jun 20, 2016 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
